(Q44275068)

1 December 2017

title

Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? (English)

1 reference

1 December 2017

0 references

1

1 reference

1 December 2017

4

Wilfrid van Pelt

1 reference

1 December 2017

3

Harry Vennema

1 reference

1 December 2017

6

Hester E de Melker

1 reference

1 December 2017

author name string

Yvonne T H P van Duynhoven

series ordinal

2

1 reference

1 December 2017

Arie H Havelaar

series ordinal

5

1 reference

1 December 2017

language of work or name

English

0 references

publication date

26 January 2010

1 reference

1 December 2017

1 reference

1 December 2017

volume

28

1 reference

1 December 2017

issue

14

1 reference

1 December 2017

page(s)

2624-2635

1 reference

Rotavirus types in Europe and their significance for vaccination

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Sensor, a Population-based Cohort Study on Gastroenteritis in the Netherlands: Incidence and Etiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Clinical trials of rotavirus vaccines in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

The promise of new rotavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Assessing the introduction of universal rotavirus vaccination in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Gastroenteritis in sentinel general practices,The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Disease burden in The Netherlands due to infections with Shiga toxin-producing Escherichia coli O157.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Incidence and cost of rotavirus hospitalizations in Denmark

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Hospital admissions for rotavirus infection in the Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Disease burden and risk factors for hospitalizations associated with rotavirus infection among children in New York State, 1989 through 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Occurrence and impact of community-acquired and nosocomial rotavirus infections--a hospital-based study over 10 y

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Estimating the number of deaths with rotavirus as a cause in England and wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Understanding DALYs (disability-adjusted life years)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Health burden in the Netherlands due to infection with thermophilic Campylobacter spp.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

The friction cost method for measuring indirect costs of disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Towards a new approach for estimating indirect costs of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

The cost-effectiveness of rotavirus vaccination in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Risk factors for norovirus, Sapporo-like virus, and group A rotavirus gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Economic analysis ofCampylobacter control in the dutch broiler meat chain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Cost-utility analysis to control Campylobacter on chicken meat: dealing with data limitations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Does Viral Diversity Matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

A one-year intensified study of outbreaks of gastroenteritis in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

A comparison of gastroenteritis in a general practice-based study and a community-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Cost and cost-effectiveness of childhood vaccination against rotavirus in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Costs of gastroenteritis in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

Nosocomial viral infections in a pediatric service: example of rotaviral gastroenteritis and respiratory syncytial viral bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

The study of infectious intestinal disease in England: socio-economic impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.014

10.1016/J.VACCINE.2010.01.014

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference